⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462417 | 0.94 | — | — | |
| SCHEMBL6462413 | 0.94 | — | — | |
| SCHEMBL4572135 | 0.92 | — | — | |
| SCHEMBL26663732 | 0.88 | — | — | |
| SCHEMBL9175960 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL10021815 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL5827953 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL18643583 | 0.84 | TFPI2 (0.31) | — | |
| SCHEMBL21220243 | 0.82 | — | — | |
| SCHEMBL31204070 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601799-A | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |